Functional interplay between histone demethylase and deacetylase enzymes

Min Gyu Lee, Christopher Wynder, Daniel A. Bochar, Mohamed Ali Hakimi, Neil Cooch, Ramin Shiekhattar

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors are a promising class of anticancer agents for the treatment of solid and hematological malignancies. The precise mechanism by which HDAC inhibitors mediate their effects on tumor cell growth, differentiation, and/or apoptosis is the subject of intense research. Previously we described a family of multiprotein complexes that contain histone deacetylase 1/2 (HDAC1/2) and the histone demethylase BHC110 (LSD1). Here we show that HDAC inhibitors diminish histone H3 lysine 4 (H3K4) demethylation by BHC110 in vitro. In vivo analysis revealed an increased H3K4 methylation concomitant with inhibition of nucleosomal deacetylation by HDAC inhibitors. Reconstitution of recombinant complexes revealed a functional connection between HDAC1 and BHC110 only when nucleosomal substrates were used. Importantly, while the enzymatic activity of BHC110 is required to achieve optimal deacetylation in vitro, in vivo analysis following ectopic expression of an enzymatically dead mutant of BHC110 (K661A) confirmed the functional cross talk between the demethylase and deacetylase enzymes. Our studies not only reveal an intimate link between the histone demethylase and deacetylase enzymes but also identify histone demethylation as a secondary target of HDAC inhibitors.

Original languageEnglish (US)
Pages (from-to)6395-6402
Number of pages8
JournalMolecular and Cellular Biology
Volume26
Issue number17
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Histone Demethylases
Histone Deacetylase Inhibitors
Histone Deacetylases
Enzymes
Histones
Histone Deacetylase 2
Histone Deacetylase 1
Multiprotein Complexes
Hematologic Neoplasms
Antineoplastic Agents
Methylation
Lysine
Cell Differentiation
Apoptosis
Growth
Research
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Functional interplay between histone demethylase and deacetylase enzymes. / Lee, Min Gyu; Wynder, Christopher; Bochar, Daniel A.; Hakimi, Mohamed Ali; Cooch, Neil; Shiekhattar, Ramin.

In: Molecular and Cellular Biology, Vol. 26, No. 17, 09.2006, p. 6395-6402.

Research output: Contribution to journalArticle

Lee, Min Gyu ; Wynder, Christopher ; Bochar, Daniel A. ; Hakimi, Mohamed Ali ; Cooch, Neil ; Shiekhattar, Ramin. / Functional interplay between histone demethylase and deacetylase enzymes. In: Molecular and Cellular Biology. 2006 ; Vol. 26, No. 17. pp. 6395-6402.
@article{d6b0b1c0d02f49de8efa7162e0bcf251,
title = "Functional interplay between histone demethylase and deacetylase enzymes",
abstract = "Histone deacetylase (HDAC) inhibitors are a promising class of anticancer agents for the treatment of solid and hematological malignancies. The precise mechanism by which HDAC inhibitors mediate their effects on tumor cell growth, differentiation, and/or apoptosis is the subject of intense research. Previously we described a family of multiprotein complexes that contain histone deacetylase 1/2 (HDAC1/2) and the histone demethylase BHC110 (LSD1). Here we show that HDAC inhibitors diminish histone H3 lysine 4 (H3K4) demethylation by BHC110 in vitro. In vivo analysis revealed an increased H3K4 methylation concomitant with inhibition of nucleosomal deacetylation by HDAC inhibitors. Reconstitution of recombinant complexes revealed a functional connection between HDAC1 and BHC110 only when nucleosomal substrates were used. Importantly, while the enzymatic activity of BHC110 is required to achieve optimal deacetylation in vitro, in vivo analysis following ectopic expression of an enzymatically dead mutant of BHC110 (K661A) confirmed the functional cross talk between the demethylase and deacetylase enzymes. Our studies not only reveal an intimate link between the histone demethylase and deacetylase enzymes but also identify histone demethylation as a secondary target of HDAC inhibitors.",
author = "Lee, {Min Gyu} and Christopher Wynder and Bochar, {Daniel A.} and Hakimi, {Mohamed Ali} and Neil Cooch and Ramin Shiekhattar",
year = "2006",
month = "9",
doi = "10.1128/MCB.00723-06",
language = "English (US)",
volume = "26",
pages = "6395--6402",
journal = "Molecular and Cellular Biology",
issn = "0270-7306",
publisher = "American Society for Microbiology",
number = "17",

}

TY - JOUR

T1 - Functional interplay between histone demethylase and deacetylase enzymes

AU - Lee, Min Gyu

AU - Wynder, Christopher

AU - Bochar, Daniel A.

AU - Hakimi, Mohamed Ali

AU - Cooch, Neil

AU - Shiekhattar, Ramin

PY - 2006/9

Y1 - 2006/9

N2 - Histone deacetylase (HDAC) inhibitors are a promising class of anticancer agents for the treatment of solid and hematological malignancies. The precise mechanism by which HDAC inhibitors mediate their effects on tumor cell growth, differentiation, and/or apoptosis is the subject of intense research. Previously we described a family of multiprotein complexes that contain histone deacetylase 1/2 (HDAC1/2) and the histone demethylase BHC110 (LSD1). Here we show that HDAC inhibitors diminish histone H3 lysine 4 (H3K4) demethylation by BHC110 in vitro. In vivo analysis revealed an increased H3K4 methylation concomitant with inhibition of nucleosomal deacetylation by HDAC inhibitors. Reconstitution of recombinant complexes revealed a functional connection between HDAC1 and BHC110 only when nucleosomal substrates were used. Importantly, while the enzymatic activity of BHC110 is required to achieve optimal deacetylation in vitro, in vivo analysis following ectopic expression of an enzymatically dead mutant of BHC110 (K661A) confirmed the functional cross talk between the demethylase and deacetylase enzymes. Our studies not only reveal an intimate link between the histone demethylase and deacetylase enzymes but also identify histone demethylation as a secondary target of HDAC inhibitors.

AB - Histone deacetylase (HDAC) inhibitors are a promising class of anticancer agents for the treatment of solid and hematological malignancies. The precise mechanism by which HDAC inhibitors mediate their effects on tumor cell growth, differentiation, and/or apoptosis is the subject of intense research. Previously we described a family of multiprotein complexes that contain histone deacetylase 1/2 (HDAC1/2) and the histone demethylase BHC110 (LSD1). Here we show that HDAC inhibitors diminish histone H3 lysine 4 (H3K4) demethylation by BHC110 in vitro. In vivo analysis revealed an increased H3K4 methylation concomitant with inhibition of nucleosomal deacetylation by HDAC inhibitors. Reconstitution of recombinant complexes revealed a functional connection between HDAC1 and BHC110 only when nucleosomal substrates were used. Importantly, while the enzymatic activity of BHC110 is required to achieve optimal deacetylation in vitro, in vivo analysis following ectopic expression of an enzymatically dead mutant of BHC110 (K661A) confirmed the functional cross talk between the demethylase and deacetylase enzymes. Our studies not only reveal an intimate link between the histone demethylase and deacetylase enzymes but also identify histone demethylation as a secondary target of HDAC inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=33747808580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747808580&partnerID=8YFLogxK

U2 - 10.1128/MCB.00723-06

DO - 10.1128/MCB.00723-06

M3 - Article

VL - 26

SP - 6395

EP - 6402

JO - Molecular and Cellular Biology

JF - Molecular and Cellular Biology

SN - 0270-7306

IS - 17

ER -